Overview

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in treating patients with nonmetastatic prostate cancer that has not responded to previous hormone therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
3,3'-diindolylmethane
Hormones